Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608348 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11617377 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10177274 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL79966 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2212574 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18151989 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28151155 | 0.96 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2537576 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11327207 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL39903 | 0.92 | P2RY2 (0.58) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8357713-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357713-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8283369-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES. INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8173690-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | LMNA 503/4885THRB 3306/4885MTOR 3142/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | LMNA 752/4885THRB 4110/4885MTOR 3153/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | LMNA 503/4885THRB 3306/4885MTOR 3142/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | LMNA 503/4885THRB 3306/4885MTOR 3142/4885 |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | XDH, PON1, OAT | LMNA 752/4885THRB 4110/4885MTOR 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.